BioMerieux (BioMerieux) Beginning Cash Position : $437 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Beginning Cash Position?

BioMerieux's Beginning Cash Position for the quarter that ended in Dec. 2023 was $437 Mil.

BioMerieux's quarterly Beginning Cash Position increased from Dec. 2022 ($544 Mil) to Jun. 2023 ($573 Mil) but then declined from Jun. 2023 ($573 Mil) to Dec. 2023 ($437 Mil).

BioMerieux's annual Beginning Cash Position increased from Dec. 2021 ($420 Mil) to Dec. 2022 ($834 Mil) but then declined from Dec. 2022 ($834 Mil) to Dec. 2023 ($577 Mil).

BioMerieux Beginning Cash Position Historical Data

The historical data trend for BioMerieux's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Beginning Cash Position Chart

BioMerieux Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

309.22

321.17

419.55

833.90

576.66

BioMerieux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															511.53	832.03	543.86	572.81	437.08

BioMerieux Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

BioMerieux Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of BioMerieux's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux (BioMerieux) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (OTCPK:BMXMF) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BIMp:UK 0RUG:UK BIM:France EYWN:Germany BIM:Austria

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (BioMerieux) Headlines

From GuruFocus

bioM�rieux Introduces GENE-UP� ENVIROPRO�

By PRNewswire PRNewswire • 02-02-2023

French multidisciplinary consortium ARPEGE awarded public funding of close to �9 million to fight antibiotic resistance

By PRNewswire PRNewswire • 01-06-2022